Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic Dermatitis: an ECZTEND Interim Analysis
Bibliographic record
Abstract
Objective• Atopic dermatitis is a chronic inflammatory disease characterized by eczematous skin lesions and multiple symptoms, including pruritus, sleep disturbance, and depression 1-4• Tralokinumab is a high-affinity, fully human monoclonal antibody designed to specifically neutralize interleukin-13, a key driver of the underlying inflammation in atopic dermatitis 5-7• Phase 3 trials have established the efficacy and safety of tralokinumab for up to 52 weeks in adult patients with moderate-to-severe atopic dermatitis 8,9• An ongoing, open-label extension trial, ECZTEND (NCT03587805), is investigating the long-term safety and efficacy of tralokinumab in patients with atopic dermatitis who participated in previous tralokinumab trials • To present interim ECZTEND efficacy data collected through April 30, 2020 from a patient cohort receiving tralokinumab for at least 56 weeks Conclusions • In this ECZTEND interim analysis of the Week 56 cohort, tralokinumab 300 mg q2w plus optional TCS demonstrated sustained long-term improvements in itch, sleep, and the extent and severity of atopic dermatitis up to Week 56, with maintenance of robust EASI response rates (61% of patients achieved EASI-90 at Week 56) • Overall, tralokinumab plus optional TCS was well tolerated in patients enrolled in ECZTEND at data cut-off, with a safety profile consistent with the parent trials Long-Term Improvements Observed in Tralokinumab-Treated Patients with Moderate-to-Severe Atopic
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.004 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.004 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".